Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition(s):CholangiocarcinomaLast Updated:June 5, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):CholangiocarcinomaLast Updated:June 5, 2023Not yet recruiting
Condition(s):Advanced or Metastatic Solid TumorsLast Updated:August 28, 2023Recruiting
Condition(s):Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System GliomaLast Updated:October 26, 2022Active, not recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:December 3, 2019Terminated
Condition(s):Stage IV Melanoma; Stage III MelanomaLast Updated:September 30, 2021Unknown status
Condition(s):Bronchial NeoplasmsLast Updated:November 3, 2022Recruiting
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:August 30, 2023Active, not recruiting
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:August 29, 2023Active, not recruiting
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:June 27, 2023Active, not recruiting
Condition(s):CancerLast Updated:September 14, 2018Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.